Individual development and uPA–receptor expression of disseminated tumour cells in bone marrow: A reference to early systemic disease in solid cancer

Nature Medicine

Volumn 1, Issue 10, 1995, Pages 1035-1039

  Heiss, Markus Maria ^a   Allgayer, Heike ^a   Gruetzner, Klaus Uwe ^a   Funke, Ilona ^a   Babic, Rudolf ^b   Jauch, Karl Walter ^a   Schildberg, Friedrich Wilhelm ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RECEPTOR; UROKINASE;

ARTICLE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; STOMACH CANCER; SYSTEMIC DISEASE; TUMOR CELL;

BONE MARROW; BONE MARROW NEOPLASMS; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; HUMAN; KERATIN; NEOPLASM CIRCULATING CELLS; PROGNOSIS; RECEPTORS, CELL SURFACE; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED;

EID: 0028885643     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1095-1035     Document Type: Article

References (33)

1. Brisco, M J. et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 343, 196-199 (1994).
2. Yokota, S. et al. Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. Blood 77, 331-339 (1991).
3. Riethmueller, G. & Johnson, J. Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancer. Curr. Opin. Immun. 4, 647-655 (1992).
4. Osborne M.P. & Rosen P.P. Detection and management of bone marrow mi-crometastases in breast cancer. Oncology 8, 25-31 (1994).
5. Moss, T.J. et al. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. New Engl. J. Med. 324, 219-226 (1991).
6. Lindemann, F, Schlimok, G., Dirschedl, P., Witte, J. & Riethmueller, G. Prognostic significance of micrometastatic tumor cells in bone marrow of colorectal cancer patients. Lancet 340, 685-689 (1992).
7. Schlimok, G. et al. Micrometastatic cancer cells in bone marrow: In vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc. natn. Acad. Sci. U.S.A. 84, 8672-8676 (1987).
8. Ghosh, A.K. et al. Detection of metastatic tumour cells in routine bone marrow smears by immunoalkaline phosphatase labelling with monoclonal antibodies. Brit. J. Haematol. 61, 21-30 (1985).
9. Heiss, M.M. et al. Detection of cytokeratin-positive cells in bone marrow used as tumor marker in gastric cancer patients, in Tumor Associated Antigens, Oncogenes, Receptors, Cytokines in Tumor Diagnosis and Therapy at the Beginning of the Nineties, Cancer of the Breast-State and Trends in Diagnosis and Therapy (ed. Klapdor, R.) 471-473 (Zuckschwerdt, Munich, New York, 1992).
10. Pantel, K. et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J. natn. Cancer Inst. 85, 1419-1423 (1993).
11. Berger, U, et al. The relationship between micrometastasis in the bone marrow, histopathologic features of the primary tumor in breast cancer and prognosis. Am. J. clin. Pathol 90, 1-6 (1988).
12. Cote, R.J., Rosen, P.P., Lesser, M.L., Old, L.J. & Osborne, M.P. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J. clin. Oncol. 9, 1749-1756 (1991).
13. Riesenberg, R. et al. Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumour cells. Histochemistry 99, 61-66 (1993).
14. Jauch, K.W., Gruetzner, U., Heiss, M.M., Funke, I. & Schildberg, F.W. Prognostic significance of early disseminated tumor cells in bone marrow of patients with gastric cancer, in First Intl. Gastric Cancer Congr., Kyoto, Japan Mar. 29-Apr. 1, 1995 (eds Nishi, M. et al.) 1021-1025 (Monduzzi Edi, Bologna, 1995).
15. Mansi, J.L. et al. The fate of bone marrow micrometastases in patients with primary breast cancer. J. clin. Oncol. 7, 445-49 (1989).
16. Fidler, I. & Kripke M.L. Metastasis results from pre-existing variant cells within a malignant tumor. Science 197, 893-895 (1977).
17. Dvorak, H.F. Tumors: Wounds that do not heal. New Engl. J. Med. 315, 1650-1659 (1986).
18. Duffy, M.J. The role of proteolytic enzymes in cancer invasion and metastasis. Clin. exp. Metastasis 10, 145-155 (1992).
19. Ossowski, L., Clunie, G., Masucci, M.T. & Blasi, F. In vivo paracrine interaction between urokinase and its receptor: Effect on tumor cell invasion. J. Cell Biol. 115, 1107-1112(1991).
20. Blasi, F. Urokinase and urokinase receptor: A paracrine/autocrine system regulation cell migration and invasiveness. BioEssays 15, 105-111 (1993).
21. Heiss, M.M. et al. Tumor-associated proteolysis and prognosis: New functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J. clin. Oncol 13, 2084-2093 (1995).
22. Nekarda, H. et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res. 54, 2900-2907 (1994).
23. Duffy, M.J. et al. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res. 50, 6827-6829 (1990).
24. Moll, R., Franke, W.W., Schiller, D.L., Geiger, B. & Krepler, R. The catalogue of human cytokeratins: Pattern of expression in normal epithelia, tumors and cultured cells. Cell 31, 11-24 (1982).
25. Breimann, L., Friedmann, J.H., Ohlsen, R.A. & Sone, CJ. Classification and Regression Trees (Waelswoth, Belmont, California, 1984).
26. Fazioli F. & Blasi F. Urokinase-type plasminogen activator and its receptor: New targets for anti-metastatic therapy? Trends Pharmac. Sci. 15, 25-29 (1994).
27. Paget, S. Distribution of secondary growths in cancer of the breast. Lancet 1, 571 (1889).
28. Wong, K.F., Chan, J.K.& Ma, S.K. Solid tumor with initial presentation in the bone marrow: A clinicopathologic study of 25 adult cases. Hematol.-Oncol 11, 35-42 (1993).
29. Frost, P., Raber, M.N. & Abbruzzese, J.L. Unknown primary tumors as a unique clinical and biological entity: A hypothesis. Cancer Bull 41, 139-141 (1989).
30. Cordell, J.L. et al. Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal antialkaline phosphatase (APAAP complexes). J. Histochem. Cytochem. 32, 219-229 (1984).
31. Dixon, W.J. et al. BMDP Statistical Software (Univ. California Press, Los Angeles, 1985).
32. Kaplan, E.L. & Meier, P. Nonparametric estimation from incomplete observation. J. Am. stat. Assoc. 53, 457-481 (1958).
33. Cox D.R. Regression models and life tables. J. R. stat Soc. (B) 34, 187-220 (1972).